BR112015014243A8 - composição de vacina para uso em populações imunocomprometidas e uso da mesma - Google Patents

composição de vacina para uso em populações imunocomprometidas e uso da mesma Download PDF

Info

Publication number
BR112015014243A8
BR112015014243A8 BR112015014243A BR112015014243A BR112015014243A8 BR 112015014243 A8 BR112015014243 A8 BR 112015014243A8 BR 112015014243 A BR112015014243 A BR 112015014243A BR 112015014243 A BR112015014243 A BR 112015014243A BR 112015014243 A8 BR112015014243 A8 BR 112015014243A8
Authority
BR
Brazil
Prior art keywords
vaccine
immunocompromised populations
vaccine composition
immunocompromised
populations
Prior art date
Application number
BR112015014243A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015014243A2 (pt
Inventor
Maltais Anna-Karin
Arwidsson Hans
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of BR112015014243A2 publication Critical patent/BR112015014243A2/pt
Publication of BR112015014243A8 publication Critical patent/BR112015014243A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112015014243A 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma BR112015014243A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077007 WO2014095944A1 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Publications (2)

Publication Number Publication Date
BR112015014243A2 BR112015014243A2 (pt) 2017-07-11
BR112015014243A8 true BR112015014243A8 (pt) 2019-10-08

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015014243A BR112015014243A8 (pt) 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma
BR112015014174A BR112015014174A2 (pt) 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015014174A BR112015014174A2 (pt) 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens

Country Status (12)

Country Link
US (2) US11065325B2 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502996A (enExample)
KR (3) KR20210007042A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014243A8 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007753A (enExample)
RU (2) RU2661407C2 (enExample)
WO (2) WO2014095944A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243817A1 (en) * 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions
ES2927797T3 (es) * 2014-09-26 2022-11-11 Seqirus Uk Ltd Vacunación de sujetos inmunocomprometidos
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
BR112022020792A2 (pt) * 2020-04-16 2022-11-29 Bayer Ag Combinações de compostos ativos e composições fungicidas compreendendo-as
LT4135519T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A4 (en) * 2022-01-10 2026-06-17 Childrens Medical Ct Corp METHODS AND COMPOSITIONS RELATING TO THE IMMUNIZATION OF DISTINCTIVE IMMUNE PATIENTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
EP2292628A3 (en) 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
US20130243817A1 (en) 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions

Also Published As

Publication number Publication date
EP2931308A1 (en) 2015-10-21
CA2895023A1 (en) 2014-06-26
KR20210007042A (ko) 2021-01-19
EP2931307B1 (en) 2018-09-12
BR112015014174A2 (pt) 2017-07-11
WO2014095943A1 (en) 2014-06-26
HK1212611A1 (zh) 2016-06-17
RU2015129028A (ru) 2017-01-23
RU2015129077A (ru) 2017-01-23
KR20150132093A (ko) 2015-11-25
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
US20150306204A1 (en) 2015-10-29
HK1213492A1 (zh) 2016-07-08
JP2016502997A (ja) 2016-02-01
MX2015007688A (es) 2015-09-07
CN104884085A (zh) 2015-09-02
RU2661408C2 (ru) 2018-07-16
EP2742952A1 (en) 2014-06-18
EP2931308B1 (en) 2018-10-10
US11065325B2 (en) 2021-07-20
KR20150132092A (ko) 2015-11-25
CN112826929A (zh) 2021-05-25
AU2013360889B2 (en) 2016-12-01
AU2013360890A1 (en) 2015-07-02
AU2013360889C1 (en) 2017-06-08
CA2895028A1 (en) 2014-06-26
EP2931307A1 (en) 2015-10-21
US20150306205A1 (en) 2015-10-29
CN104870010A (zh) 2015-08-26
RU2661407C2 (ru) 2018-07-16
JP2016502996A (ja) 2016-02-01
MX2015007753A (es) 2016-01-08
WO2014095944A1 (en) 2014-06-26
BR112015014243A2 (pt) 2017-07-11
AU2013360889A1 (en) 2015-07-02
AU2013360890B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
BR112015014243A2 (pt) composição de vacina para uso em populações imunocomprometidas
MD4841B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
BR112015001313A2 (pt) composições de vacina
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
BR112015011439A2 (pt) composto, composição farmacêutica, composição de vacina, e, uso de um composto
MX369474B (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
CO6761399A2 (es) Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina
BR112016021985A8 (pt) formulação farmacêutica e composto
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
BR112012029304A2 (pt) copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas
MX382924B (es) Composición para prevenir infección por mycoplasma spp.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112015028025A8 (pt) composição farmacêutica adaptada para administração oral e uso de uma composição
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements